Literature DB >> 825583

Discovery, chemistry, and activity of amikacin.

H Kawaguchi.   

Abstract

Elucidation of the mechanism of R-factor-mediated resistance to aminoglycoside antibiotics was a noteworthy scientific achievement that led to the search for and design of new structural modifications of aminoglycosides that would render them resistant to inactivation by bacterial enzymes and increase their activity against resistant organisms. Amikacin is a derivative of kanamycin A, obtained through acetylation with the L(-)-gamma-amino-alpha-hydroxybutyryl side chain at the C-1 amino group of the deoxystreptamine moiety. Its antibacterial activity is generally equal to or greater than that of kanamycin against sensitive organisms, and it is also active against aminoglycoside-resistant strains of various species. The special significance of the site of acylation and the configuration of the acid side chain were established by obtaining all possible positional and configurational isomers. Studies of a series of amikacin analogs indicated that the alpha-hydroxyl group and the terminal basic function in the side chain both play a very important role in the antimicrobial activity of amikacin.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 825583     DOI: 10.1093/infdis/135.supplement_2.s242

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

1.  Pharmacokinetics of intravenous amikacin after rapid and slow infusion with special reference to hemodialysis.

Authors:  J C Pechere; R Dugal; M M Pechere
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1979       Impact factor: 2.441

2.  Influence of the route of administration on the pharmacokinetics of amikacin.

Authors:  J M Lanao; A Dominguez-Gil; J M Tabernero; L Corbacho
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

3.  UK-18892, a new aminoglycoside: an in vitro study.

Authors:  R Wise; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  1978-08       Impact factor: 5.191

Review 4.  Safety and tolerability profile of second-line anti-tuberculosis medications.

Authors:  Geetha Ramachandran; Soumya Swaminathan
Journal:  Drug Saf       Date:  2015-03       Impact factor: 5.606

5.  Hear us! Accounts of people treated with injectables for drug-resistant TB.

Authors:  A Almeida; M Adjuntsov; W Bushura; E Delgado; M Drasher; M Fernando-Pancho; M Gasane; M V Ianoşi; E Lessem; A Musah; Ş Răduţ; C H Sánchez Ríos; K S Soe; N Venkatesan; V V Villegas; J Stillo
Journal:  Public Health Action       Date:  2021-09-21

6.  Evidence for a chromosomal site specifying amikacin resistance in multiresistant Serratia marcescens.

Authors:  J F John; W F McNeill; K E Price; P A Kresel
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

7.  Amikacin assay in serum by high-performance liquid chromatography.

Authors:  S K Maitra; T T Yoshikawa; C M Steyn; L B Guze; M C Schotz
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

8.  Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection.

Authors:  M E Huth; A J Ricci; A G Cheng
Journal:  Int J Otolaryngol       Date:  2011-10-25

9.  Functional characterization of bacteria isolated from ancient arctic soil exposes diverse resistance mechanisms to modern antibiotics.

Authors:  Gabriel G Perron; Lyle Whyte; Peter J Turnbaugh; Jacqueline Goordial; William P Hanage; Gautam Dantas; Michael M Desai
Journal:  PLoS One       Date:  2015-03-25       Impact factor: 3.240

10.  Directed evolution of aminoglycoside phosphotransferase (3') type IIIa variants that inactivate amikacin but impose significant fitness costs.

Authors:  Joseph R Kramer; Ichiro Matsumura
Journal:  PLoS One       Date:  2013-10-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.